{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:31:10Z","timestamp":1782307870279,"version":"3.54.5"},"reference-count":36,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"abstract":"<jats:p>Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells expressing the CD33 receptor by means of a monoclonal antibody conjugated to a cytotoxic agent, calicheamicin. Treatment of acute myeloid leukemia (AML) with gemtuzumab ozogamicin may result in liver injury. We reviewed the course of 23 patients who were given gemtuzumab ozogamicin for AML that had relapsed after hematopoietic cell transplantation. Liver toxicity was assessed through physical examination, serum tests, histologic examination, and hepatic venous pressure measurements. Liver injury developed in 11 patients after gemtuzumab ozogamicin administration; it was manifested as weight gain, ascites, and jaundice in 7 patients. Seven patients died with persistent liver dysfunction and either multiorgan failure or sepsis at a median of 40 days after gemtuzumab ozogamicin infusion. Portal pressure measurements were elevated in 2 patients. Results of liver histologic examination in 5 patients showed sinusoidal injury with extensive sinusoidal fibrosis, centrilobular congestion, and hepatocyte necrosis. Six patients experienced AML remission that was sustained for at least 60 days after gemtuzumab ozogamicin infusion. In summary, hepatic sinusoidal liver injury developed after gemtuzumab ozogamicin infusion. Histology showed striking deposition of sinusoidal collagen, suggesting that gemtuzumab ozogamicin targets CD33+ cells residing in hepatic sinusoids as the mechanism for its hepatic toxicity.<\/jats:p>","DOI":"10.1182\/blood.v99.7.2310","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:33:52Z","timestamp":1034361232000},"page":"2310-2314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":210,"title":["Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy"],"prefix":"10.1182","volume":"99","author":[{"given":"Pankaj","family":"Rajvanshi","sequence":"first","affiliation":[{"name":"From the Gastroenterology\/Hepatology, Oncology, and Pathology Sections, Clinical Research Division, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Shulman","sequence":"additional","affiliation":[{"name":"From the Gastroenterology\/Hepatology, Oncology, and Pathology Sections, Clinical Research Division, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Sievers","sequence":"additional","affiliation":[{"name":"From the Gastroenterology\/Hepatology, Oncology, and Pathology Sections, Clinical Research Division, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[{"name":"From the Gastroenterology\/Hepatology, Oncology, and Pathology Sections, Clinical Research Division, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221121727900_B1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2401663","article-title":"Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.","volume":"14","author":"Bernstein","year":"2000","journal-title":"Leukemia."},{"key":"2020021221121727900_B2","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood."},{"key":"2020021221121727900_B3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically [abstract].","volume":"240","author":"Zein","year":"1988","journal-title":"Science."},{"key":"2020021221121727900_B4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse.","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol."},{"key":"2020021221121727900_B5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer."},{"key":"2020021221121727900_B6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002770000239","article-title":"Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate.","volume":"80","author":"Neumeister","year":"2001","journal-title":"Ann Hematol."},{"key":"2020021221121727900_B7","first-page":"206b","article-title":"Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676): relationship to hematopoietic stem cell transplantation [abstract].","volume":"96","author":"Sievers","year":"2000","journal-title":"Blood."},{"key":"2020021221121727900_B8","first-page":"814","article-title":"Report on the CD33 cluster workshop: biochemical and genetic characterization of gp67.","volume-title":"Leucocyte typing IV: White Cell Differentiation Antigens.","author":"Peiper","year":"1989","edition":"1st ed."},{"key":"2020021221121727900_B9","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood.V83.11.3188.3188","article-title":"Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen.","volume":"83","author":"Tchilian","year":"1994","journal-title":"Blood."},{"key":"2020021221121727900_B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2559.1995.tb00192.x","article-title":"Pathology of the liver in leukaemia and lymphoma: a study of 110 autopsies.","volume":"26","author":"Scheimberg","year":"1995","journal-title":"Histopathology."},{"key":"2020021221121727900_B11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(00)04217-3","article-title":"Repopulation of liver endothelium by bone marrow-derived cells.","volume":"357","author":"Gao","year":"2001","journal-title":"Lancet."},{"key":"2020021221121727900_B12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ajcp\/88.3.354","article-title":"Rapid diagnosis of invasive cytomegalovirus infection by examination of tissue specimens in centrifugation culture [abstract].","volume":"88","author":"Gleaves","year":"1987","journal-title":"Am J Clin Pathol."},{"key":"2020021221121727900_B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/clinids\/14.1.38","article-title":"Hepatitis due to herpes simplex virus in marrow-transplant recipients.","volume":"14","author":"Johnson","year":"1992","journal-title":"Clin Infect Dis."},{"key":"2020021221121727900_B14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00007890-199504150-00017","article-title":"Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients.","volume":"59","author":"Shulman","year":"1995","journal-title":"Transplantation."},{"key":"2020021221121727900_B15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0016-5085(79)90330-5","article-title":"Wedged and free hepatic venous pressure measured with a balloon catheter.","volume":"76","author":"Groszmann","year":"1979","journal-title":"Gastroenterology."},{"key":"2020021221121727900_B16","first-page":"1617","article-title":"Hepatobiliary complications of hematopoietic stem cell transplantation.","volume-title":"Schiff's Diseases of the Liver.","author":"Strasser","year":"1999","edition":"8th ed."},{"key":"2020021221121727900_B17","first-page":"21","article-title":"Transjugular liver biopsy in bone marrow transplantation.","volume":"11","author":"Carreras","year":"1993","journal-title":"Bone Marrow Transplant."},{"key":"2020021221121727900_B18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.510310224","article-title":"Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat.","volume":"31","author":"Wang","year":"2000","journal-title":"Hepatology."},{"key":"2020021221121727900_B19","first-page":"206","article-title":"Idiopathic portal hypertension associated with cytotoxic drugs.","volume":"43","author":"Shepherd","year":"1990","journal-title":"J Clin Oncol."},{"key":"2020021221121727900_B20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(86)90266-4","article-title":"Hepatic veno-occlusive disease.","volume":"81","author":"Rollins","year":"1986","journal-title":"Am J Med."},{"key":"2020021221121727900_B21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation.","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology."},{"key":"2020021221121727900_B22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.1840190515","article-title":"Venocclusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms.","volume":"19","author":"Shulman","year":"1994","journal-title":"Hepatology."},{"key":"2020021221121727900_B23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease).","volume":"22","author":"Deleve","year":"2002","journal-title":"Semin Liver Dis."},{"key":"2020021221121727900_B24","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.4049\/jimmunol.165.12.7150","article-title":"Inhibition of TNF-\u03b1 produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.","volume":"165","author":"Onda","year":"2000","journal-title":"J Immunol."},{"key":"2020021221121727900_B25","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021221121727900_B26","first-page":"837","article-title":"CD33 cluster workshop report.","volume-title":"Leucocyte Typing V: White Cell Differentiation Antigens.","author":"Peiper","year":"1995"},{"key":"2020021221121727900_B27","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/hep.1840210606","article-title":"Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver.","volume":"21","author":"Blakolmer","year":"1995","journal-title":"Hepatology."},{"key":"2020021221121727900_B28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/jhep.2001.21900","article-title":"Heterogeneity and plasticity of hepatocyte lineage cells.","volume":"33","author":"Sell","year":"2001","journal-title":"Hepatology."},{"key":"2020021221121727900_B29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1053\/jhep.2000.7713","article-title":"Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver.","volume":"31","author":"Golden-Mason","year":"2000","journal-title":"Hepatology."},{"key":"2020021221121727900_B30","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular resonse to tissue injury.","volume":"275","author":"Friedman","year":"2000","journal-title":"J Biol Chem."},{"key":"2020021221121727900_B31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/jhep.2001.23505","article-title":"Drug-induced liver injury: mechanisms and test systems.","volume":"33","author":"Bissell","year":"2001","journal-title":"Hepatology."},{"key":"2020021221121727900_B32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/0016-5085(80)90911-7","article-title":"An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation.","volume":"79","author":"Shulman","year":"1980","journal-title":"Gastroenterology."},{"key":"2020021221121727900_B33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1126\/science.356266","article-title":"Bone marrow origin of hepatic macrophages (Kupffer cells) in humans.","volume":"201","author":"Gale","year":"1978","journal-title":"Science."},{"key":"2020021221121727900_B34","first-page":"G692","article-title":"Intermittence of blood flow in liver sinusoids, studied by high-resolution in vivo microscopy.","volume":"269","author":"MacPhee","year":"1995","journal-title":"Am J Physiol."},{"key":"2020021221121727900_B35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.1840080305","article-title":"A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation.","volume":"8","author":"Shulman","year":"1988","journal-title":"Hepatology."},{"key":"2020021221121727900_B36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/gast.2001.20947","article-title":"Immunology of the healthy liver: old questions and new insights.","volume":"120","author":"Mehal","year":"2001","journal-title":"Gastroenterology."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/7\/2310\/1681741\/2310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/7\/2310\/1681741\/2310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:14:48Z","timestamp":1581560088000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/7\/2310\/106698\/Hepatic-sinusoidal-obstruction-after-gemtuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.7.2310","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4,1]]}}}